SH-K01

SH-K01 is an orally bioavailable small molecule inhibitor specifically targeting the KRAS G12C mutation, developed by Nanjing Sanhome Pharmaceutical. It functions by covalently and irreversibly binding to the cysteine residue at position 12 of the KRAS protein, trapping the protein in its inactive GDP-bound conformation. This action prevents the activation of downstream signaling pathways, such as the RAF-MEK-ERK (MAPK) pathway, which are critical for the proliferation and survival of cancer cells. SH-K01 is primarily being developed for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer, that harbor the KRAS G12C mutation.